Aptevo Therapeutics Unveils Preclinical Data for Trispecific Antibody APVO451 in Solid Tumors
Aptevo Therapeutics Inc. has presented preclinical data for its trispecific antibody candidate, APVO451, at the SITC Annual Meeting on November 8, 2025. APVO451 targets immune suppression in solid tumors, including urothelial, breast, and pancreatic cancers, by engaging nectin-4 and utilizing a proprietary CD3 binding domain to activate T cells. The company is advancing APVO451 through ongoing preclinical studies to support future clinical development.
Aptevo Therapeutics Inc. has announced the first presentation of preclinical data for its new trispecific antibody candidate, APVO451. The data were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8, 2025. APVO451 is designed to address immune suppression in the tumor microenvironment of hard-to-treat solid tumors, including urothelial, breast, and pancreatic cancers. The molecule targets nectin-4 on tumor cells and incorporates Aptevo’s proprietary CRIS-7-derived CD3 binding domain to activate T cells, as well as engaging CD40 to restore the function of antigen-presenting cells. The company reported that APVO451 is advancing through ongoing preclinical studies with the goal of supporting future clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1099359) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
